MNPR Company Profile and Key Details

Q: Who are the executives of MNPR?

Dr. Chandler D. Robinson M.B.A., M.D., M.Sc., MBA, MScCo-Founder, Chief Executive Officer, Pres & DirectorMs. Kim R. Tsuchimoto CPAChief Financial Officer, Sec., Treasurer & DirectorMr. Andrew J. Cittadine M.B.A.Chief Operating OfficerDr. Patrice P. Rioux M.D., Ph.D.Acting Chief Medical Officer

NASDAQ : MNPR

Monopar Therapeutics

$61.35

-4.17-6.36%

At Close 4:00 PM

64.5

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Monopar Therapeutics Inc. (MNPR) stock declined over -6.36%, trading at $61.35 on NASDAQ, down from the previous close of $65.52. The stock opened at $65.02, fluctuating between $60.85 and $65.68 in the recent session.

Stock Snapshot

65.52

Prev. Close

410.56M

Market Cap

60.845

Day Low

-33.16

P/E Ratio

-1.85

EPS (TTM)

-0.53

Cash Flow per Share

65.02

Open

6.69M

Number of Shares

65.68

Day High

64.1%

Free Float in %

0.37

Book Value

151.73K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
May 12, 2026	65.44	66.00	60.85	61.35	152.27K
May 11, 2026	64.12	67.90	63.41	65.52	166.55K
May 08, 2026	61.56	65.58	61.56	63.58	183.34K
May 07, 2026	63.25	66.16	58.53	62.43	198.04K
May 06, 2026	56.95	64.28	56.81	63.86	288.48K
May 05, 2026	54.51	57.00	51.75	56.88	94.48K
May 04, 2026	52.98	54.82	52.98	54.64	68.51K
Apr 30, 2026	50.26	53.63	50.26	52.15	79.64K
Apr 29, 2026	53.99	54.54	50.07	50.12	143.93K
Apr 28, 2026	53.85	55.42	53.65	54.48	78.42K
Apr 27, 2026	52.82	54.03	52.35	54.02	60.57K
Apr 23, 2026	53.58	53.79	52.30	53.24	198.33K
Apr 22, 2026	53.15	53.81	51.66	53.30	152.61K
Apr 21, 2026	55.07	56.69	52.24	52.71	185.51K
Apr 20, 2026	56.22	57.92	54.11	54.70	183.32K
Apr 17, 2026	59.04	59.43	56.22	56.22	243.9K
Apr 16, 2026	57.52	58.10	55.92	57.70	256.99K
Apr 14, 2026	56.87	60.08	56.44	57.92	238.67K
Apr 13, 2026	56.22	58.12	55.46	56.08	169.38K
Apr 10, 2026	57.45	57.76	54.80	56.08	201.78K

Contact Details

Wilmette, IL 60091

United States

https://www.monopartx.com 847 388 0349

About Company

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Espa�ol de Investigaci�n en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.

Stock Peers

ARGX

-0.47-0.06%

argenx SE$812.81 REGN

10.64+1.49%

Regeneron Pharmaceuticals, Inc.$723.41 UTHR

11.86+2.08%

United Therapeutics Corporation$581.74 MDGL

13.23+2.66%

Madrigal Pharmaceuticals, Inc.$510.26 VRTX

13.12+3.01%

Vertex Pharmaceuticals Incorporated$448.29 PRAX

11.39+3.43%

Praxis Precision Medicines, Inc.$343.20 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 KRYS

-2.57-0.82%

Krystal Biotech, Inc.$310.31 ALNY

7.19+2.52%

Alnylam Pharmaceuticals, Inc.$292.03 ASND

-1.02-0.43%

Ascendis Pharma A/S$237.65

Frequently Asked Questions

What is the current Monopar Therapeutics Inc. (MNPR) stock price?

Monopar Therapeutics Inc. (NASDAQ: MNPR) stock price is $61.35 in the last trading session. During the trading session, MNPR stock reached the peak price of $65.68 while $60.85 was the lowest point it dropped to. The percentage change in MNPR stock occurred in the recent session was -6.36% while the dollar amount for the price change in MNPR stock was - $4.17.

MNPR's industry and sector of operation?

The NASDAQ listed MNPR is part of Biotechnology industry that operates in the broader Healthcare sector. Monopar Therapeutics Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of MNPR?

Dr. Chandler D. Robinson M.B.A., M.D., M.Sc., MBA, MSc
Co-Founder, Chief Executive Officer, Pres & Director
Ms. Kim R. Tsuchimoto CPA
Chief Financial Officer, Sec., Treasurer & Director
Mr. Andrew J. Cittadine M.B.A.
Chief Operating Officer
Dr. Patrice P. Rioux M.D., Ph.D.
Acting Chief Medical Officer

How MNPR did perform over past 52-week?

MNPR's closing price is 116.02% higher than its 52-week low of $28.40 where as its distance from 52-week high of $105.00 is -41.57%.

How many employees does MNPR have?

Number of MNPR employees currently stands at 14.

Link for MNPR official website?

Official Website of MNPR is: https://www.monopartx.com

How do I contact MNPR?

MNPR could be contacted at phone 847 388 0349 and can also be accessed through its website. MNPR operates from 1000 Skokie Boulevard, Wilmette, IL 60091, United States.

How many shares of MNPR are traded daily?

MNPR stock volume for the day was 151.73K shares. The average number of MNPR shares traded daily for last 3 months was 177.57K.

What is the market cap of MNPR currently?

The market value of MNPR currently stands at $410.56M with its latest stock price at $61.35 and 6.69M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	14
Beta	1.59
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

Employees	14
Beta	1.59
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

MNPR Company Profile and Key Details

Monopar Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Frequently Asked Questions

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Company Overview

Technical Performance

Dividend & Fair Value

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Earnings & Analyst Outlook

Valuation Metrics

Key Takeaways

Price Forecast & Outlook